# Efficacy and Safety Study of SPL7013 Gel to Prevent the Recurrence of Bacterial Vaginosis (BV)

> **NCT02237950** · PHASE3 · COMPLETED · sponsor: **Starpharma Pty Ltd** · enrollment: 586 (actual)

## Conditions studied

- Bacterial Vaginosis

## Interventions

- **DRUG:** Metronidazole oral tablets 500mg
- **DRUG:** 1% SPL7013 Gel
- **DRUG:** Placebo gel

## Key facts

- **NCT ID:** NCT02237950
- **Lead sponsor:** Starpharma Pty Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-10-13
- **Primary completion:** 2016-12-09
- **Final completion:** 2017-02-22
- **Target enrollment:** 586 (ACTUAL)
- **Last updated:** 2019-07-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02237950

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02237950, "Efficacy and Safety Study of SPL7013 Gel to Prevent the Recurrence of Bacterial Vaginosis (BV)". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02237950. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*